GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXIBF) » Definitions » Construction In Progress

WXIBF (WuXi Biologics (Cayman)) Construction In Progress : $0 Mil (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Construction In Progress?

WuXi Biologics (Cayman)'s quarterly construction in progress increased from Jun. 2023 ($0 Mil) to Dec. 2023 ($1,926 Mil) but then declined from Dec. 2023 ($1,926 Mil) to Jun. 2024 ($0 Mil).

WuXi Biologics (Cayman)'s annual construction in progress increased from Dec. 2021 ($1,707 Mil) to Dec. 2022 ($2,286 Mil) but then declined from Dec. 2022 ($2,286 Mil) to Dec. 2023 ($1,926 Mil).

WuXi Biologics (Cayman) Construction In Progress Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Construction In Progress Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 544.32 1,362.68 1,707.04 2,285.67 1,925.67

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2,285.67 - 1,925.67 -

WuXi Biologics (Cayman) Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

WuXi Biologics (Cayman) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXIBF) » Definitions » Construction In Progress
Comparable Companies
HKSE:01801 HKSE:01177 HKSE:09926 HKSE:06990 HKSE:01548 HKSE:01877 HKSE:01530 HKSE:09969 HKSE:01952 HKSE:09995 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
WXXWY:USA 02269:Hong Kong 1FW2:Germany
Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
Website
https://www.wuxibiologics.com
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has a global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.